Literature DB >> 24435977

The role of plasma IDO activity as a diagnostic marker of patients with colorectal cancer.

M Cavia-Saiz1, P Muñiz Rodríguez, B Llorente Ayala, M García-González, M J Coma-Del Corral, C García Girón.   

Abstract

High levels of indoleamine 2,3-dioxygenase (IDO) are involved in tumour escape mechanisms. The aim of this study is the evaluation of L-kynurenine of plasma as marker of diagnostic and prognostic in patients with colorectal cancer. The study included 78 patients with colorectal cancer, of whom 15 % were in stage I/II, 30 % in stage III, and 55 % in stage IV, and was compared with a control group of 70 healthy subjects. The receiver operating characteristic (ROC) curve analysis showed an area under the curve of 0.917, with a specificity of 100 % and with a sensitivity to detect cancer of the colon of 85.2 %, taking 1.83 μM as a cut-off point. The overall survival analysis also indicated that patients with low levels of L-kynurenine in plasma increased survival rate after 45 months of follow-up (P = 0.032). These results show that the plasma levels of L-kynurenine could be a good biomarker to differentiate individuals with colorectal cancer from healthy individuals.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24435977     DOI: 10.1007/s11033-014-3080-2

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  28 in total

1.  Serum sHLA-G levels: a useful indicator in distinguishing colorectal cancer from benign colorectal diseases.

Authors:  Cheng-Bao Zhu; Chuan-Xin Wang; Xin Zhang; Jian Zhang; Wei Li
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

2.  Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas.

Authors:  Klaus Laimer; Birgit Troester; Frank Kloss; Georg Schafer; Peter Obrist; Alexander Perathoner; Johannes Laimer; Gerald Brandacher; Michael Rasse; Raimund Margreiter; Albert Amberger
Journal:  Oral Oncol       Date:  2011-03-25       Impact factor: 5.337

3.  The dimensions of the CRC problem.

Authors:  L V Karsa; T A Lignini; J Patnick; R Lambert; C Sauvaget
Journal:  Best Pract Res Clin Gastroenterol       Date:  2010-08       Impact factor: 3.043

4.  Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP.

Authors:  Soranobu Ninomiya; Takeshi Hara; Hisashi Tsurumi; Masato Hoshi; Nobuhiro Kanemura; Naoe Goto; Senji Kasahara; Masahito Shimizu; Hiroyasu Ito; Kuniaki Saito; Yoshinobu Hirose; Tetsuya Yamada; Takeshi Takahashi; Mitsuru Seishima; Tsuyoshi Takami; Hisataka Moriwaki
Journal:  Ann Hematol       Date:  2010-10-12       Impact factor: 3.673

5.  Changes in the levels of thioredoxin and indoleamine-2,3-dioxygenase activity in plasma of patients with colorectal cancer treated with chemotherapy.

Authors:  Monica Cavia-Saiz; Pilar Muñiz; Reyes De Santiago; Marta Herreros-Villanueva; Carlos Garcia-Giron; Ana Sofia Lopez; Maria Jesus Coma-Del Corral
Journal:  Biochem Cell Biol       Date:  2012-01-18       Impact factor: 3.626

Review 6.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

7.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.

Authors:  Catherine Uyttenhove; Luc Pilotte; Ivan Théate; Vincent Stroobant; Didier Colau; Nicolas Parmentier; Thierry Boon; Benoît J Van den Eynde
Journal:  Nat Med       Date:  2003-09-21       Impact factor: 53.440

8.  Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.

Authors:  Gerald Brandacher; Alexander Perathoner; Ruth Ladurner; Stefan Schneeberger; Peter Obrist; Christiana Winkler; Ernst R Werner; Gabriele Werner-Felmayer; Helmut G Weiss; Georg Göbel; Raimund Margreiter; Alfred Königsrainer; Dietmar Fuchs; Albert Amberger
Journal:  Clin Cancer Res       Date:  2006-02-15       Impact factor: 12.531

9.  Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma.

Authors:  Ke Pan; Hui Wang; Min-shan Chen; Hua-kun Zhang; De-sheng Weng; Jun Zhou; Wei Huang; Jian-jun Li; Hai-feng Song; Jian-chuan Xia
Journal:  J Cancer Res Clin Oncol       Date:  2008-04-26       Impact factor: 4.553

Review 10.  Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use.

Authors:  M J Duffy; A van Dalen; C Haglund; L Hansson; E Holinski-Feder; R Klapdor; R Lamerz; P Peltomaki; C Sturgeon; O Topolcan
Journal:  Eur J Cancer       Date:  2007-05-18       Impact factor: 9.162

View more
  8 in total

1.  Sodium Tanshinone IIA Sulfonate as a Potent IDO1/TDO2 Dual Inhibitor Enhances Anti-PD1 Therapy for Colorectal Cancer in Mice.

Authors:  Rongjie Zhang; Yuanfeiyi Wang; Dan Liu; Qing Luo; Peixin Du; Haiyan Zhang; Wenshuang Wu
Journal:  Front Pharmacol       Date:  2022-04-27       Impact factor: 5.988

2.  Expression and Prognostic Value of Indoleamine 2,3-dioxygenase in Pancreatic Cancer.

Authors:  Tao Zhang; Xiang-Long Tan; Yong Xu; Zi-Zheng Wang; Chao-Hui Xiao; Rong Liu
Journal:  Chin Med J (Engl)       Date:  2017-03-20       Impact factor: 2.628

Review 3.  Metabolomics Biomarkers for Detection of Colorectal Neoplasms: A Systematic Review.

Authors:  Vanessa Erben; Megha Bhardwaj; Petra Schrotz-King; Hermann Brenner
Journal:  Cancers (Basel)       Date:  2018-07-27       Impact factor: 6.639

4.  miR-448 targets IDO1 and regulates CD8+ T cell response in human colon cancer.

Authors:  Qiong Lou; Ruixian Liu; Xiangling Yang; Weiqian Li; Lanlan Huang; Lili Wei; Huiliu Tan; Nanlin Xiang; Kawo Chan; Junxiong Chen; Huanliang Liu
Journal:  J Immunother Cancer       Date:  2019-08-07       Impact factor: 13.751

Review 5.  Biomarkers for detecting colorectal cancer non-invasively: DNA, RNA or proteins?

Authors:  Alexandre Loktionov
Journal:  World J Gastrointest Oncol       Date:  2020-02-15

Review 6.  Not Only Immune Escape-The Confusing Role of the TRP Metabolic Pathway in Carcinogenesis.

Authors:  Iwona Kwiatkowska; Justyna Magdalena Hermanowicz; Alicja Przybyszewska-Podstawka; Dariusz Pawlak
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

7.  Prognostic value of the PrPC-ILK-IDO1 axis in the mesenchymal colorectal cancer subtype.

Authors:  Alexandre Ghazi; Delphine Le Corre; Camilla Pilati; Julien Taieb; Thomas Aparicio; Audrey Didelot; Shoukat Dedhar; Claire Mulot; Karine Le Malicot; Fatima Djouadi; Aurélien de Reynies; Jean-Marie Launay; Pierre Laurent-Puig; Sophie Mouillet-Richard
Journal:  Oncoimmunology       Date:  2021-06-28       Impact factor: 8.110

8.  Expression Pattern and Clinicopathological Relevance of the Indoleamine 2,3-Dioxygenase 1/Tryptophan 2,3-Dioxygenase Protein in Colorectal Cancer.

Authors:  I-Chien Chen; Kuen-Haur Lee; Ying-Hua Hsu; Wei-Ran Wang; Chuan-Mu Chen; Ya-Wen Cheng
Journal:  Dis Markers       Date:  2016-08-08       Impact factor: 3.434

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.